Qingdao Haier Biomedical Co.,Ltd (SHA:688139)

SHA:688139 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	2,242	2,274	2,272	2,855	2,119	1,372
Other Revenue	13.58	9.85	9.24	8.62	7.31	30.08
Revenue	2,256	2,284	2,281	2,864	2,126	1,402
Revenue Growth (YoY)	1.00%	0.13%	-20.36%	34.72%	51.63%	38.47%
Cost of Revenue	1,201	1,190	1,174	1,490	1,061	695.47
Gross Profit	1,055	1,094	1,107	1,374	1,065	706.56
Selling, General & Admin	521.47	471.73	476.68	513.72	388.03	238.76
Research & Development	322.83	306.17	320.64	292.47	236.31	150.72
Other Operating Expenses	-1.32	-6.48	-7.25	2.34	1.63	13.03
Operating Expenses	854.82	787.08	793.97	809.08	622.71	403.54
Operating Income	200.57	306.58	312.95	564.67	441.98	303.02
Interest Expense	-3.57	-3.41	-3.51	-2.69	-2.89	-0.08
Interest & Investment Income	63.84	71.46	118.64	95.02	483.95	113.2
Currency Exchange Gain (Loss)	7.06	4.46	-7.72	3.58	4.14	-8.54
Other Non Operating Income (Expenses)	-3.44	-1.83	-1.68	-1.49	0.56	-0.61
EBT Excluding Unusual Items	264.47	377.25	418.67	659.1	927.74	406.99
Gain (Loss) on Sale of Investments	8.5	5.47	2.06	-7.01	10.21	3.83
Gain (Loss) on Sale of Assets	0.18	0.23	-1.6	-0.76	-0.52	-5.27
Asset Writedown	-1.86	-1.86	-2.36	-	-	-
Other Unusual Items	27.99	20.87	17.72	24	23.44	18.68
Pretax Income	299.28	401.96	434.49	675.34	960.87	424.24
Income Tax Expense	10.2	20.95	22.43	63.36	111.7	40.11
Earnings From Continuing Operations	289.08	381.01	412.06	611.97	849.17	384.12
Minority Interest in Earnings	-14.05	-14.38	-5.99	-11.18	-4.14	-3.17
Net Income	275.03	366.63	406.07	600.79	845.04	380.95
Net Income to Common	275.03	366.63	406.07	600.79	845.04	380.95
Net Income Growth	-24.02%	-9.71%	-32.41%	-28.90%	121.82%	109.24%
Shares Outstanding (Basic)	316	316	317	318	316	317
Shares Outstanding (Diluted)	316	316	317	318	318	326
Shares Change (YoY)	-0.33%	-0.37%	-0.20%	0.06%	-2.43%	30.55%
EPS (Basic)	0.87	1.16	1.28	1.89	2.67	1.20
EPS (Diluted)	0.87	1.16	1.28	1.89	2.66	1.17
EPS Growth	-23.76%	-9.38%	-32.27%	-28.95%	127.35%	60.27%
Free Cash Flow	139.72	164.96	72.08	338.18	387.11	607.63
Free Cash Flow Per Share	0.44	0.52	0.23	1.06	1.22	1.87
Dividend Per Share	0.470	0.470	0.515	0.450	0.500	0.380
Dividend Growth	-8.74%	-8.74%	14.44%	-10.02%	31.61%	111.11%
Gross Margin	46.78%	47.89%	48.53%	47.97%	50.08%	50.40%
Operating Margin	8.89%	13.42%	13.72%	19.72%	20.79%	21.61%
Profit Margin	12.19%	16.05%	17.80%	20.98%	39.75%	27.17%
Free Cash Flow Margin	6.19%	7.22%	3.16%	11.81%	18.21%	43.34%
EBITDA	302.01	411.38	410.67	626.73	491.15	325.87
EBITDA Margin	13.39%	18.01%	18.00%	21.88%	23.10%	23.24%
D&A For EBITDA	101.43	104.8	97.72	62.06	49.17	22.85
EBIT	200.57	306.58	312.95	564.67	441.98	303.02
EBIT Margin	8.89%	13.42%	13.72%	19.72%	20.79%	21.61%
Effective Tax Rate	3.41%	5.21%	5.16%	9.38%	11.63%	9.46%
Revenue as Reported	2,256	2,284	2,281	2,864	2,126	1,402
Advertising Expenses	-	24.88	31.82	25.41	14.24	11.5

Source: S&P Global Market Intelligence. Standard template. Financial Sources.